Inmune Bio Inc. (INMB)
NASDAQ (CM) NASDAQ (CM) Primary 
INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. Mark Lowdell - Chief Scientific Officer Dr. CJ Barnum - Head, Neuroscience Conference Call Participants Denis Reznik - Raymond James George Farmer - Scotiabank Tom Shrader - BTIG Laura Suriel - Alliance Global Partners Operator Greetings. And welcome to the INmune Bio First Quarter 2025 Earnings Call.
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call.
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns.
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial for XPro in Alzheimer's is fully enrolled, with topline data expected around May-June 2025, marking a pivotal moment. XPro's selective TNF inhibition has shown significant reductions in key biomarkers like ptau-217 and neurofilament light, indicating strong efficacy in neurodegenerative diseases.
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows potential in early-stage trials for Alzheimer's, with crucial phase 2 data expected in Q2 2025. Financially, INMB has limited runway, with cash sufficient to fund operations only into Q3 2025, necessitating successful trial outcomes for further funding.
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Gary Nachman - Raymond James George Farmer - Scotiabank Joel Beatty - Baird Thomas Shrader - BTIG Operator Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded.
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate resistant prostate cancer market is projected to reach $20.70 billion by 2031. INMB completed enrollment of AD02 Phase 2 study, using XPro for patients with Alzheimer's Disease expected in Q3 of 2024, with clinical data expected 6 months after last patient recruited.
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG George Farmer - Scotiabank Operator Greetings, and welcome to the INmune Bio Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro
INmune Bio is developing immunotherapies for cancer and Alzheimer's, focusing on TNF and NK cell platforms. Their lead drug candidate, XPro, is in Phase 2 trials for early Alzheimer's disease and has shown promising anecdotal results. INKmune, another key candidate, is in Phase 1/2 trials for metastatic castration-resistant prostate cancer.
INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but continues to make progress with a potential transformative data readout by spring 2024.
